On October 12, CANSINOBIO rose 5.31% in regular trading to HK$36.82, with turnover of HK$9.55 million. The rebound was attributed to improving sentiment across the Hong Kong innovative drug and vaccine sector following several consecutive sessions of decline.

After a sharp pullback driven by Moderna's overnight plunge and a Citigroup downgrade, vaccine and innovative drug stocks staged a sentiment-driven recovery. CANSINOBIO, as a previously active mRNA vaccine concept stock, attracted funds flowing back. On the fundamental side, its collaboration with Depths Bio on an mRNA personalized tumor vaccine remains in early development, while overseas revenue surged more than 47-fold year-on-year in the first half, making internationalization a key growth engine.

CANSINOBIO is a clinical-stage Chinese vaccine company.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)